FREEDOM OF INFORMATION REQUESTS APRIL 2013
Request / Response
FoI 636 – received 4 April 2013
1.  Do you have or adhere to a:
·  Formulary
·  Traffic Light List
2.  How often is this formulary updated?
Please attach any relevant documents
3.  Do you have any plans to develop a formulary or any of the other documents detailed above?
4.  When are the formulary/ other documents due to be published?
5.  Will you utilise any other organisation's formularies in developing this formulary? / The Barnsley area formulary is available at the following link www.barnsleyformulary.nhs.uk. The formulary is updated on a regular basis when changes are made by the Area Prescribing Committee, the Committee meet on a monthly basis.
I have also attached a copy of the traffic light list.
The Barnsley formulary is a joint formulary across Barnsley CCG, BHNFT and the Barnsley Business Delivery Unit of SWYFT and all three organisations contribute to development of the formulary via the Area Prescribing Committee.

FoI 637 – received 4 April 2013
Q1 Has the CCG had any discussions with the local pharmaceutical committee regarding the provision of health services by community pharmacies in your area?
(Please note, services may include smoking cessation, minor ailments, weight management, EHC, vascular risk checks, Chlamydia screening, vaccinations etc)
Q2 Where such a discussion has been held, please could you give me the following details:
a)The date of the meeting
b)A full list of the services discussed
c)A full list of the attendees
d)A copy of the minutes of the meetings / BarnsleyCCGholds no recorded information in relation to this enquiry.
Anydiscussions or meetings which have been held withLPC members have been informal andnotminuted by the CCG.
FoI 638 – received 8 April 2013
1)  Are you familiar with the new NICE guidance published in December 2012 regarding the approved access to advanced skin cancer treatments ipilimumab (Yervoy) (TA268) and vemurafenib (Zelboraf) (TA269)?
Yes No
If so, how is it being adopted locally?
______
2)  Are you currently making ipilimumab and vemurafenib routinely available to those who need it following the publication of the guidance on 12th December 2012?
Yes No
If not, why not?
______
3)  If you answered “yes” to Question 2, did you make ipilimumab and vemurafenib routinely available to those who need it by 12th March 2013, the three month implementation deadline following the publication of NICE guidance?
Yes No
If not, what is the rationale for this?
______
4)  If you answered “yes” to Question 2, when exactly did you make ipilimumab and vemurafenib routinely available to those who need it?
Before 1st January 2013
January 2013
February 2013
March 2013
April 2013
5)  Have ipilimumab and vemurafenib now been incorporated into your local formulary?
Yes No
If not, why not?
______
6)  Had ipilimumab and vemurafenib been incorporated into your local formulary by 12th March 2013?
Yes No
If not, why not?
______
7)  Have relevant clinicians in your area been advised of the new NICE guidance on ipilimumab and vemurafenib?
Yes No
If not, why not?
______
8)  How many applications for funding through Independent Funding Requests (IFRs) for ipilimumab (Yervoy) have you received since 12th March 2013?
______
Of these applications, have any been refused?
Yes No
If so, how many and why?
______
9)  How many applications for funding through Independent Funding Requests (IFRs) for vemurafenib (Zelboraf) have you received since the publication of the NICE guidance (TA269) in December 2012 for the treatment of Melanoma (BRAF V600 mutation positive, unresectable metastatic)?
______
Of these applications, have any been refused?
Yes No
If so, how many and why?
______
10)  Following Sir David Nicholson’s letter to NHS Chief Executives in August 2012 confirming the 1st April 2013 deadline for the introduction of the NHS Compliance Regime for Technology Appraisals, are you planning to make information about the availability of ipilimumab and vemurafenib available?
Yes No
If so, when are you planning to publish it?
______
11)  Are you in the process of, or have you already carried out, a budgetary assessment relating to the impact of the positive guidance for the above treatments in your area?
Yes No
If so, do you have an estimated figure of the potential cost of the positive guidance?
______ /
FoI 639 – received 11 April 2013
Could you please supply the names and email addresses of your staff operating under job titles such as Head of Marketing & Communications, Communications Manager or Officer, Account Manager - Communications etc., ideally anybody in the Communications unit. / Kirsty Waknell, Communications and Engagement Manager, email:
FoI 640 – received 12 April 2013
I would like the contact details for each of the 5 continuing healthcare commissioning teams within the Barnsley area. / There is only one commissioning team for the Continuing HealthcareTeam in Barnsley which is:-
Barnsley Clinical Commissioning Group
c/o Hillder House
49-51 Gawber Road
Barnsley
South Yorkshire
S75 2PY
Telephone: 01226 433756
FoI 641 – received 12 April 2013
Please can you email me an Organisation Chart for the finance and accountancy function at the CCG. /
FoI 642 – received 16 April 2013
Q1 - Please detail all new measures your CCG has put in place for 2013/14 to limit GP referrals for any procedures deemed non-urgent or “low-clinical priority”. Please explain the rationale for making each of these changes.
Q2 - Please state how much money the CCG estimates the measures outlined in the response to Q1 will save in 2013/14.
Q3 - Please detail any specific changes the CCG has made for 2013/14 to the criteria for referring patients for any of the following procedures or treatments:
·  Knee surgery/replacements
·  Hip impingement/replacements/resurfacing
·  Cataract surgery
·  Tonsillectomies
·  Bariatric surgery
·  In vitro fertilisation (IVF)
·  Open MRI scans
·  Carpal tunnel syndrome
·  Dupuytren’s contracture /
FoI 643 – received 19 April 2013
1) Please could you provide me with a copy of the current diabetes guidelines (as of 12 April 2013) that are being utilised by the CCG
2) Where there is a current Local Enhanced Service (LES) for diabetes for the CCG, please can you provide a copy.
3) Please can you provide a copy or link to the current formulary being utilised by the CCG (as of 12 April 2013)
4) Please can you provide details of any prescribing targets or incentive schemes specific to diabetes or diabetes products for the year 2013 -2014
5) Please could you provide a copy or link to the commissioning plan for the CCG for year 2013 – 2014
If this address is not the appropriate address for a FOI enquiry - please could you acknowledge and forward to the appropriate contact. /
FoI 644 – received 23 April 2013
Please advise which commissioning support unit (if any) you are receiving commissioning support services from. Please detail all commissioning support services you are receiving from the commissioning support unit, along with contract details for each service e.g. start date, end date, and value of contract. / Q1. West and South Yorkshire and Bassetlaw CSU
Q2. Business Intelligence
Business Support
Procurement
Finance
Corporate Governance
Communications and Engagement
Human Resources
Organisational Health
CHC / FNC
Individual Funding Reviews
Equality and Diversity
Q3. The start date for the contracts is 1 April 2013 and the end date of 31 March 2014. Unfortunately the value of the contract is exempt under the Public authority’s own commercial activities.
FoI 645 – received 23 April 2013
I’m currently updating our records and contact details and was hoping you could assist me with the name and email address of the current commissioning Manager of dermatology for the Barnsley CCG please. / Barnsley CCG does not have a specific Commissioning Manager for Dermatology.
All our Acute Contracts have Contract Managers assigned to them. Therefore if an issue arises with Dermatology at a specific hospital then this would be picked up by the appropriate Contract Manager. This is the way that we do our business and it is all part of a wider team the contact in the first instance would be .
FoI 646 – received 23 April 2013
/
FoI 647 – received 24 April 2013
/
FoI 648 – received 30 April 2013
I require the name, position and any contact detailsofthe people who are functioning as the Diabetes Clinical Lead and/or Long Term Conditions Lead for theBarnsley Clinical Commissioning Group that has recently been formed. / Dr Rob Farmer
GP Clinical Lead and Elected Member of the CCG Governing Body

FoI 649 – received 30 April 2013
Do you currently have a registered nurse in post on your governing body as one of the two clinical members required by legislation?
If yes, when was the post holder appointed? Is it currently a substantive or an interim appointment?
Have you appointed any other nurses or someone with a nursing background to your executive team, for example as a director of nursing, chief nurse or other role? / Do you currently have a registered nurse in post on your governing body as one of the two clinical members required by legislation? Yes
If yes, when was the post holder appointed? Is it currently a substantive or an interim appointment? January 2013 full time substantive Chief Nurse
Have you appointed any other nurses or someone with a nursing background to your executive team, for example as a director of nursing, chief nurse or other role? As above full time substantive Chief Nurse